Seizinger Bernd R. 4
4 · Aprea Therapeutics, Inc. · Filed Mar 14, 2024
Insider Transaction Report
Form 4
Seizinger Bernd R.
Director
Transactions
- Purchase
Tranche B Warrant
2024-03-13+3,430→ 3,430 totalFrom: 2024-03-13→ Common Stock (3,430 underlying) - Purchase
Tranche A Warrant
2024-03-13+3,430→ 3,430 totalFrom: 2024-03-13→ Common Stock (3,430 underlying) - Purchase
Common Stock
2024-03-13$7.29/sh+6,860$50,009→ 33,685 total
Footnotes (6)
- [F1]The exercise price of the Tranche A Warrants is as follows: 3,430 shares of the Company's common stock at the exercise price of $7.29 per share or warrants for an exercise price of $7.29 minus $0.001 per share.
- [F2]Tranche A Warrants shall expire on March 13, 2027; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for ATRN-119, and (ii) the daily VWAP of the Common Stock equals or exceeds $14.58 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred.
- [F3]The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.
- [F4]The exercise price of the Tranche B Warrants is as follows: 3,430 shares of the Company's common stock at the exercise price of $9.1125 per share or warrants for an exercise price of $9.1125 minus $0.001 per share.
- [F5]Tranche B Warrants shall expire on March 13, 2029; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for APR-1051, and (ii) the daily VWAP of the Common Stock equals or exceeds $18.225 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred.
- [F6]The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.